Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT05760547

The Translational Initiative to Map Epigenetics in Aging (TIME-A)

The Translational Initiative to Map Epigenetics in Aging (TIME-A) study aims to advance our understanding of the connections between epigenetics, lifestyle, demographics, and health and aging.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

TIME-A is a longitudinal research initiative. Anyone who has ever taken an Index test registered through Elysium Health is eligible to participate. Participation involves answering questions that will be administered via a survey format. Research participants' survey responses will be combined with their epigenetic Index data with the primary aim of identifying the contributions of 1) environmental and lifestyle factors, 2) general health, and 3) medical history, on biological age. Exploratory aims include the development of epigenetic signatures that are predictive of health status, and exploring the relationship between epigenetically-derived health phenotypes and biological age. These findings will lay the foundation for personalized health recommendations using Index (including, but not limited to: workout routines, diets, supplement regimens, medications, lifestyle changes).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All adults aged 18 and above
  • Have registered at least one Index kit via the Elysium Health website
  • Able and willing to provide digital consent to the Research Consent Form, and the TIME-A Research Subject Consent Form

Exclusion criteria

  • Consent to participate not given

Treatment and study plan

Primary outcomes

  1. Effect of environmental and lifestyle factors on biological age

    Time frame: At baseline and throughout study (approximately every 6 months up to 120 months)

    Univariate and multivariate statistical methods will be used to identify which environmental and lifestyle factors (from TIME-A survey responses) influence biological age.

  2. Effect of general health on biological age

    Time frame: At baseline and throughout study (approximately every 6 months up to 120 months)

    Univariate and multivariate statistical methods will be used to identify which general health characteristics (from TIME-A survey responses) influence biological age.

  3. Effect of medical history on biological age

    Time frame: At baseline and throughout study (approximately every 6 months up to 120 months)

    Univariate and multivariate statistical methods will be used to identify the impact of medical history (from TIME-A survey responses) on biological age.

Other outcomes

  1. Develop epigenetic signatures that are predictive of health status

    Time frame: At baseline and throughout study (approximately every 6 months up to 120 months)

    DNA methylation data and TIME-A survey responses will be combined. Supervised and unsupervised machine learning methods will be used to generate novel methylation-derived predictors of participants' survey responses.

Study contacts

Contact information is provided by the study sponsor or research team.

Ryan Dellinger, PhD

CONTACT

[email protected]

(888) 220 6436

Sponsors and collaborators

Lead sponsor

Elysium Health

Industry

Registry information

Acronym: TIME-A

Important dates

Study start
2023
Primary completion
2033
Study completion
2033
First posted
Mar 8, 2023
Registry last updated
Mar 8, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.